<SEC-DOCUMENT>0001193125-25-196482.txt : 20250905
<SEC-HEADER>0001193125-25-196482.hdr.sgml : 20250905
<ACCEPTANCE-DATETIME>20250905060516
ACCESSION NUMBER:		0001193125-25-196482
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250905
FILED AS OF DATE:		20250905
DATE AS OF CHANGE:		20250905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollomics Inc.
		CENTRAL INDEX KEY:			0001944885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41670
		FILM NUMBER:		251294936

	BUSINESS ADDRESS:	
		STREET 1:		989 EAST HILLSDALE BLVD.
		STREET 2:		STE 220
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		1-650-209-4055

	MAIL ADDRESS:	
		STREET 1:		989 EAST HILLSDALE BLVD.
		STREET 2:		STE 220
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d27073d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of Foreign Private Issuer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>under the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of September 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-41670</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Apollomics Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#8217;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>989 E. Hillsdale Blvd., Suite 220 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Foster City, California 94404 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;</FONT> &#8195;&#8195;&#8195;&#8195;Form <FONT STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment of Certain Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a meeting of the board of directors of the Company (the &#8220;Board&#8221;) on and as of September&nbsp;4, 2025, the Board appointed Messrs. <FONT
STYLE="white-space:nowrap">Yi-An</FONT> Chu and Chen-Huan Jan as directors of the Company. Following these changes and the previously announced appointments of directors, the Company&#8217;s Board is comprised of the following seven members: Messrs.
<FONT STYLE="white-space:nowrap">Hung-Wen</FONT> (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, <FONT STYLE="white-space:nowrap">Po-Jen</FONT> Hsueh, <FONT STYLE="white-space:nowrap">Hsien-Shu</FONT> Tsai, <FONT
STYLE="white-space:nowrap">Yi-An</FONT> Chu and Chen-Huan Jan. Messrs. Moses Chen, <FONT STYLE="white-space:nowrap">Po-Jen</FONT> Hsueh, <FONT STYLE="white-space:nowrap">Hsien-Shu</FONT> Tsai, <FONT STYLE="white-space:nowrap">Yi-An</FONT> Chu and
Chen-Huan Jan are independent directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Constitution of Audit Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a meeting of the board of directors of the Company (the &#8220;Board&#8221;) on and as of September&nbsp;4, 2025, the Board appointed Messrs. <FONT
STYLE="white-space:nowrap">Po-Jen</FONT> Hsueh, <FONT STYLE="white-space:nowrap">Hsien-Shu</FONT> Tsai and <FONT STYLE="white-space:nowrap">Yi-An</FONT> Chu as members of the Company&#8217;s audit committee, with Mr.&nbsp;Tsai serving as the
chairman of such committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Constitution of Compensation Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a meeting of the board of directors of the Company (the &#8220;Board&#8221;) on and as of September&nbsp;4, 2025, the Board appointed Messrs. Moses
Chen, <FONT STYLE="white-space:nowrap">Hsien-Shu</FONT> Tsai and <FONT STYLE="white-space:nowrap">Yi-An</FONT> Chu as members of the compensation committee, with Mr.&nbsp;Moses Chen serving as the chairman of such committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Constitution of Nominating and Corporate Governance Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a meeting of the board of directors of the Company (the &#8220;Board&#8221;) on and as of September&nbsp;4, 2025, the Board appointed Messrs. Moses
Chen, <FONT STYLE="white-space:nowrap">Po-Jen</FONT> Hsueh and Chen-Huan Jan as members of the corporate governance committee, with Mr.&nbsp;Jan serving as the chairman of such committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment of Chairman of the Board, Chief Executive Officer, Chief Operating Officer and Chief Financial Officer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a meeting of the board of directors of the Company (the &#8220;Board&#8221;) on and as of September&nbsp;4, 2025, the Board appointed
Mr.&nbsp;Howard Chen as Chairman of the Board and Chief Executive Officer of the Company, Mr.&nbsp;Yi-Kuei Chen as the Chief Operating Officer of the Company and Mr.&nbsp;Peter Lin as the Chief Financial Officer of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Biographical Information of the New Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Yi-An</FONT> (Frank) Chu </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Yi-An</FONT> Chu, with extensive backgrounds in finance, investment, and technology, has over 30 years of professional
experience spanning the capital markets and the high-tech industry. He is the former Chief Financial Officer of Global Investment Holdings (ticker: 3701) and has previously held senior leadership positions across several major corporate groups,
including Compal, VIA Technologies, and Foxconn. His professional expertise covers corporate finance, investment management, strategic planning, and business operations, with a proven track record in leading investment projects and corporate
restructuring initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Chu has also served as a board director or representative of numerous publicly listed companies, such as Go TrustID,
Gorilla Technology, Yeastern Technology, and GCT Semiconductor (later merged into WIN Semiconductors). His corporate governance experience highlights his ability to bridge financial strategy with operational execution, guiding companies through
critical growth and transformation stages. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to his CFO role, Mr.&nbsp;Chu was Vice President of Kuan Bao Technology (acting General Manager),
Director of Investment at Tong Bao Optoelectronics, and Senior Manager at Compal Electronics. Earlier in his career, he worked as Investment Director at VIA Technologies, Assistant Vice President at Foxconn&#8217;s PCB division, and Senior
Electronic Research Analyst at Capital Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Chu received his MBA in Finance and Investment from Baruch College, City University of New
York, and a BS in Electrical Engineering from National Chiao Tung University. His unique blend of engineering background and financial acumen allows him to navigate both the technical and strategic dimensions of investment and corporate management.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Chen-Huan (Jack) Jan </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Chen-Huang (Jack) Jan
is a seasoned academic and business leader whose distinguished career spans over three decades across education, international business diplomacy, and corporate strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Jan is the president and chief consultant of Jan Elite International Co., Ltd., independent director of Gemtek Technology and a consultant of
SelectFlorida. He earned his Ph.D. in Mathematics from the University of Louisiana at Lafayette and served as a visiting assistant professor at the University of West Florida, an associate professor at National Pingtung University, where he founded
the <FONT STYLE="white-space:nowrap">Taiwan-U.S</FONT> Commercial Forum organized with American Institute in Taiwan (AIT) to promote international collaboration. Beyond academia, Dr.&nbsp;Jan has been deeply engaged in strengthening <FONT
STYLE="white-space:nowrap">Taiwan-U.S.</FONT> relations and had served as Governor of the American Chamber of Commerce in Kaohsiung. He has received multiple honors, including recognition from the American Institute in Taiwan, the U.S. Department of
Commerce, and U.S. Idaho state government. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Biographical Information of the Chairman of the Board, Chief Operating Officer and Chief Financial
Officer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Hung-Wen&nbsp;(Howard)</FONT> Chen </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr, Chen is the Founder and Chairman of Gemtek Technology Co., Ltd. and the Former Chairman and CEO of Polaris Pharmaceuticals, Inc., and currently serving as
an Executive Director of Polaris. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University,
Taiwan. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">He later founded Gemtek Technology, which has since grown into one of the world&#8217;s leading manufacturers of professional wireless broadband equipment,
with a strong presence in international markets. In recognition of his contributions to the technology industry, Mr.&nbsp;Chen received the Outstanding Alumni Award from National Tsing Hua University in 2010 and was honored with the ERSO Award in
2013, one of the most prestigious accolades in Taiwan&#8217;s technology sector. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2019, Polaris Pharmaceuticals faced a severe financial crisis, as
many of its clinical trials remained uncertain while costs and expenses exceeded the company&#8217;s capacity. During this difficult period, Mr.&nbsp;Chen stepped in and took decisive action to stabilize the company. Under his leadership, Polaris
underwent a comprehensive strategic reorganization, and with the efforts of his management team, the company achieved a remarkable turnaround, culminating in a successful IPO in Taiwan in June 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Yi-Kuei Chen </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yi-Kuei Chen with backgrounds in
biotechnology and venture capital, is <FONT STYLE="white-space:nowrap">a&nbsp;co-founder&nbsp;of</FONT> Maxpro Ventures. Mr.&nbsp;Chen&#8217;s professional expertise in asset management has led to his successful execution of more than 60 private
equity investment transactions in the USA and the Asia-Pacific region. His past investments include Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee, HEC Pharma, and ACT Genomics Holdings, amongst others. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior <FONT STYLE="white-space:nowrap">to&nbsp;co-founding&nbsp;Maxpro</FONT> Ventures, Mr.&nbsp;Chen was
the Senior Director of Integral Group. He was jointly in charge of Integral&#8217;s Asian transaction process, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc.,
BioLite, Inc., and Flora International Group Co., Ltd.. From 1999 to 2012, Mr.&nbsp;Chen held various senior management positions in the investment division at Central Investment Holdings. During that period, his successful investments included
Tanox and Biopure, to name just a few. In 2002, a significant transaction that Mr.&nbsp;Chen had made was the acquisition of SEEDNet by New Century InfoComm Tech. He also served on several corporate boards, such as Concord Fund Company, Singfor Life
Insurance Company, and CTCI Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Chen received an MBA from Syracuse University and an MS from the University of Minnesota. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Peter Lin </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter KH Lin, CAIA, MBA, MIS is a seasoned
corporate executive and investor with a distinguished career spanning biotechnology, finance, and private equity. He has held key leadership roles as Chief Financial Officer at Tanvex Biopharma, Tanvex CDMO, Tanvex Biopharma USA, and Tanvex Biologic
Corporation in Taiwan, where he oversaw financial strategy, capital operations, and corporate governance across global entities. Prior to Tanvex, Peter served as CFO of Theragent, a pioneering CDMO specializing in gene and cell therapy, where he
helped shape the financial foundation of a high-growth startup in the advanced therapeutics space. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter&#8217;s career is also deeply rooted in the
financial industry. As a principal and investment manager at Solarium Capital, a boutique private equity firm, he led acquisitions and equity investments across diverse sectors including technology, food and beverage, and real estate. Earlier in his
career, after earning his MBA, Peter joined WesCorp as an investment research manager, where he directed a credit research team managing a $32&nbsp;billion fixed-income portfolio&#8212;one of the largest structured credit portfolios globally. His
team conducted <FONT STYLE="white-space:nowrap">in-depth</FONT> analysis of U.S. and international structured finance instruments, including MBS, ABS, CDOs, and corporate debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to his executive roles, Peter serves on the boards of multiple companies spanning biotechnology, medical devices, media, publishing, and real
estate private equity ventures. He holds a bachelor&#8217;s degree in Business Administration from the University of California, Berkeley, a master&#8217;s degree in Information Systems from Claremont Graduate University, and an MBA from the
University of Southern California. He is also a Chartered Alternative Investment Analyst (CAIA) charterholder, underscoring his expertise in alternative investments and global capital markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this Form <FONT STYLE="white-space:nowrap">6-K</FONT> relating to the PIPE Subscription Agreements, the appointment and departure
of certain directors and the cancellation of the extraordinary general meeting of members is incorporated by reference into the Company&#8217;s registration statements under the Securities Act, including its registration statements on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-272559)</FONT> and Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File Nos. <FONT STYLE="white-space:nowrap">333-278430,</FONT> <FONT
STYLE="white-space:nowrap">333-278431</FONT> and <FONT STYLE="white-space:nowrap">333-279549),</FONT> and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Correction to the Company&#8217;s Form 6-K filed September 4, 2025 due to inadvertent clerical error</I>: Following the issuance of the PIPE Shares,
Hung-Wen (Howard) Chen, who was appointed Chairman of the Company&#8217;s board of directors (&#8220;Board&#8221;) as described below, and his affiliates beneficially own approximately 42% of the outstanding Class&nbsp;A ordinary shares and Maxpro
Investment Co., Ltd. and its affiliates beneficially own approximately 4.9% of the outstanding Class&nbsp;A ordinary shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">


<IMG SRC="g27073g76v41.jpg" ALT="LOGO" STYLE="width:1.25764in;height:0.318056in;">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>APOLLOMICS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Howard Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date September&nbsp;5, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Chairman of the Board</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g27073g76v41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27073g76v41.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $5V82!097)E
M>B!'86UB;V$    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,U
M,0  DI(  @    ,U,0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\:U*** "BBB@ K"\9^&(O%_A6ZTF29K:9]LEM<H/FMYD.Y)![A@/PR.];M%
J'/\ @VX\1R:,;?QA9Q0:C:/Y+7$$@:.\ 4$2J.JYSR"!R#17044 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
